蘑菇视频APP 11.19.2009
VisEn Launches New Osteosense® 800 and Vivotag® 800 Fluorescence Molecular Imaging Agents
Expands VisEn鈥檚 Fluorescence Molecular Imaging Agent Portfolio to Enable Enhanced Multiplexed Readouts of Key Biomarkers in Research and Drug Development
BEDFORD, MA (November 19, 2009)-- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new OsteoSense庐 800 imaging agent for targeting areas of bone turnover and microcalcification in vivo. The new 800 nm OsteoSense agent complements VisEn鈥檚 OsteoSense 680 and 750 products, and is expected to further expand the utilization of this agent family in enabling in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastasis. In addition, VisEn has launched a new near infrared label, VivoTag 800庐 to add an additional wavelength channel to its current line of VivoTag fluorochromes which are used to label specific ligands of interest in a wide variety of in vivo and in vitro imaging applications. Both of the new 800 nm agents are well suited for imaging quantification on the VisEn FMT 2500鈩� LX quantitative tomography imaging system, which also has expanded wavelength capabilities to enable simultaneous imaging of up to four agents and biologies of interest in vivo.
VisEn鈥檚 proprietary fluorescence imaging agents and labels are designed to provide the industry鈥檚 broadest and most robust range of biologically-specific imaging readouts in vivo. VisEn now offers over 30+ different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways. VisEn agent brands include ProSense庐, IntegriSense鈩�, AngioSense鈩�, OsteoSense庐, Annexin-VivoTM, MMPSense鈩�, Cat B FAST鈩�, Cat K FAST鈩� and ReninSense鈩� FAST. VisEn also offers its specialized in vivo agent labeling platforms, including its proprietary VivoTag庐 fluorescence labeling dyes for custom agent development, and its NanoSpark庐 labeling nanoparticles, all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in in vivo imaging. All VisEn agents and labels, including the new OsteoSense庐 800 and VivoTag庐 800 agents, are designed for in vivo biomarker quantification using VisEn鈥檚 Fluorescence Molecular Tomography (FMT鈩�) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems. VisEn agents are also designed to enable in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and cellular-based imaging systems. With a focus on translational research and results, all of VisEn鈥檚 technologies are designed to generate translational data linking pre-clinical research into clinical medicine.
About VisEn Medical Inc.
VisEn鈥檚 in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT鈩�) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn鈥檚 FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications designed for their specific pre-clinical and clinical research areas. Additional information can be found at .
Contact:
Robert Sandler
SVP, Marketing
VisEn Medical Inc.
C. 416.274.8166
O. 647.350.1881
E. rsandler@visenmedical.com
W.